Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients

Clinical Cancer Research

Volumn 18, Issue 4, 2012, Pages 1101-1108

  Ciarimboli, Giuliano ^a   Lancaster, Cynthia S ^b   Schlatter, Eberhard ^a   Franke, Ryan M ^b   Sprowl, Jason A ^b   Pavenstädt, Hermann ^a   Massmann, Vivian ^a   Guckel, Denise ^a   Mathijssen, Ron H J ^c   Yang, Wenjian ^b   Pui, Ching Hon ^b   Relling, Mary V ^b   Herrmann, Edwin ^a   Sparreboom, Alex ^b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CREATININE; METHOTREXATE; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG EFFICACY; ENZYME INHIBITION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; KIDNEY CANCER; KIDNEY FUNCTION; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE EXCRETION; MALE; MOUSE; NEPHRECTOMY; NONHUMAN; OCT2 GENE; ONCOGENE; PRIORITY JOURNAL; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL LINE; CISPLATIN; CREATININE; FEMALE; HUMANS; KIDNEY TUBULES, PROXIMAL; MALE; MICE; MICE, KNOCKOUT; ORGANIC CATION TRANSPORT PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84863177864     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2503     Document Type: Article

References (34)

1. Stevens LA, Levey AS. Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol 2009;20:2305-13.
2. Breyer MD, Qi Z. Better nephrology for mice-and man. Kidney Int 2010;77:487-9.
3. Olsen NV, Ladefoged SD, Feldt-Rasmussen B, Fogh-Andersen N, Jordening H, Munck O. The effects of cimetidine on creatinine excretion, glomerular filtration rate and tubular function in renal transplant recipients. Scand J Clin Lab Invest 1989;49:155-9. (Pubitemid 19112171)
4. Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther 2009;86:396-402.
5. Ciarimboli G, Deuster D, Knief A, Sperling M, Holtkamp M, Edemir B, et al. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol 2010;176:1169-80.
6. Ciarimboli G, Ludwig T, Lang D, Pavenstädt H, Koepsell H, Piechota HJ, et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 2005;167:1477-84. (Pubitemid 41713303)
7. Filipski KK, Loos WJ, Verweij J, Sparreboom A. Interaction of cisplatin with the human organic cation transporter 2. Clin Cancer Res 2008;14:3875-80.
8. Yokoo S, Yonezawa A, Masuda S, Fukatsu A, Katsura T, Inui K, et al. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharmacol 2007;74:477-87. (Pubitemid 46963232)
9. Yonezawa A, Masuda S, Nishihara K, Yano I, Katsura T, Inui K, et al. Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem Pharmacol 2005;70:1823-31. (Pubitemid 41612013)
10. Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther 2006;319:879-86.
11. Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, et al. Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther 2009;85:155-63.
12. Schlatter E, Schafer JA. Electrophysiological studies in principal cells of rat cortical collecting tubules. ADH increases the apical membrane Na+-conductance. Pflugers Arch 1987;409:81-92. (Pubitemid 17096635)
13. Wilde S, Schlatter E, Koepsell H, Edemir B, Reuter S, Pavenstädt H, et al. Calmodulin-associated post-translational regulation of rat organic cation transporter 2 in the kidney is gender dependent. Cell Mol Life Sci 2009;66:1729-40.
14. Busch AE, Karbach U, Miska D, Gorboulev V, Akhoundova A, Volk C, et al. Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol 1998;54:342-52. (Pubitemid 28368824)
15. Ciarimboli G, Koepsell H, Iordanova M, Gorboulev V, Dürner B, Lang D, et al. Individual PKC-phosphorylation sites in organic cation transporter 1 determine substrate selectivity and transport regulation. J Am Soc Nephrol 2005;16:1562-70. (Pubitemid 41716463)
16. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007;446:758-64. (Pubitemid 46582031)
17. Treviño LR, Shimasaki N, Yang W, Panetta JC, Cheng C, Pei D, et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 2009;27:5972-8.
18. de Jongh FE, Gallo JM, Shen M, Verweij J, Sparreboom A. Population pharmacokinetics of cisplatin in adult cancer patients. Cancer Chemother Pharmacol 2004;54:105-12. (Pubitemid 39044238)
19. Lee WK, Reichold M, Edemir B, Ciarimboli G, Warth R, Koepsell H, et al. Organic cation transporters OCT1, 2, and 3 mediate high-affinity transport of the mutagenic vital dye ethidium in the kidney proximal tubule. Am J Physiol Renal Physiol 2009;296:F1504-13.
20. Motohashi H, Sakurai Y, Saito H, Masuda S, Urakami Y, Goto M, et al. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol 2002;13:866-74. (Pubitemid 34274082)
21. Pietig G, Mehrens T, Hirsch JR, Cetinkaya I, Piechota H, Schlatter E, et al. Properties and regulation of organic cation transport in freshly isolated human proximal tubules. J Biol Chem 2001;276:33741-6.
22. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-266.
23. Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985;28:830-8. (Pubitemid 16156326)
24. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 1992;38:1933-53.
25. Imamura Y, Murayama N, Okudaira N, Kurihara A, Okazaki O, Izumi T, et al. Prediction of fluoroquinolone-induced elevation in serum creatinine levels: a case of drug-endogenous substance interaction involving the inhibition of renal secretion. Clin Pharmacol Ther 2011;89:81-8.
26. Holle SK, Ciarimboli G, Edemir B, Neugebauer U, Pavenstädt H, Schlatter E, et al. Properties and regulation of organic cation transport in freshly isolated mouse proximal tubules analyzed with a fluorescence reader-based method. Pflugers Arch 2011;462:359-69.
27. Jonker JW, Wagenaar E, Van Eijl S, Schinkel AH. Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol Cell Biol 2003;23:7902-8. (Pubitemid 37271485)
28. Eisner C, Faulhaber-Walter R, Wang Y, Leelahavanichkul A, Yuen PS, Mizel D, et al. Major contribution of tubular secretion to creatinine clearance in mice. Kidney Int 2010;77:519-26.
29. Amphoux A, Vialou V, Drescher E, Brüss M, Mannoury La Cour C, Rochat C, et al. Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology 2006;50:941-52. (Pubitemid 43810126)
30. Sato Y, Kobayashi E, Hakamata Y, Kobahashi M, Wainai T, Murayama T, et al. Chronopharmacological studies of ketamine in normal and NMDA epsilon1 receptor knockout mice. Br J Anaesth 2004;92:859-64. (Pubitemid 38771689)
31. Köttgen A, Pattaro C, Böger CA, Fuchsberger C, Olden M, Glazer NL, et al. New loci associated with kidney function and chronic kidney disease. Nat Genet 2010;42:376-84.
32. Chambers JC, Zhang W, Lord GM, van der Harst P, Lawlor DA, Sehmi JS, et al. Genetic loci influencing kidney function and chronic kidney disease. Nat Genet 2010;42:373-5.
33. López-Parra M, Telleria N, Titos E, Planagumà A, González-Périz A, Arroyo V, et al. Gene expression profiling of renal dysfunction in rats with experimental cirrhosis. J Hepatol 2006;45:221-9.
34. Sansoè G, Ferrari A, Castellana CN, Bonardi L, Villa E, Manenti F, et al. Cimetidine administration and tubular creatinine secretion in patients with compensated cirrhosis. Clin Sci (Lond) 2002;102:91-8. (Pubitemid 34177805)